This project is Memorial Sloan-Kettering Cancer Center's (MSKCC) application to become a Network Lead Academic Participating Site for the NCI National Clinical Trials Network (NCTN). The MSKCC project aims are scientific leadership in development of NCTN trials, scientific leadership in the activities of the NCTN and NCI Scientific Steering Committees, patient accrual on NCTN Trials, and mentoring junior investigators in clinical trial research. MSKCC has the resources to both bring strong scientifically driven studies to the network and to participate in studies brought forth by other network participants. MSKCC has a multidisciplinary team of investigators committed to translational research, a large patient population amenable to participation in clinical trials, an superb infrastructure to support such trials. MSKCC has full membership in Alliance for Clinical Trials in Oncology, GOG and RTOG and is an affiliate member of ECOG. MSKCC has strong leadership and expertise in advanced imaging and participates in ACRIN studies on a case-by-case basis. The multiple Principal Investigators in this Network Lead Academic Site U10 are experienced leaders in the Network Groups with a track record of meeting these scientific, accrual and mentoring aims. As a large center focused solely on cancer, we have a particular expertise and commitment to the NCTN mission of evaluating rare tumors.
As a Network Lead Academic Participating Site MSKCC will be a leader in the scientific development, conduct and accrual of NCTN clinical trials with the overall goal of developing new treatments for cancer patients. This will be achieved through definitive, randomized, clinical treatment and advanced imaging trials across a broad range of diseases and diverse patient populations, as well as development efforts preliminary to those trials.
|Baljevic, Muhamed; Dumitriu, Bogdan; Lee, Ju-Whei et al. (2016) Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta Haematol 136:210-218|
|Carey, Lisa A; Berry, Donald A; Cirrincione, Constance T et al. (2016) Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol 34:542-9|
|Hertz, Daniel L; Owzar, Kouros; Lessans, Sherrie et al. (2016) Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res 22:4890-4900|
|Luskin, Marlise R; Gimotty, Phyllis A; Smith, Catherine et al. (2016) A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI Insight 1:|
|Goss, Paul E; Ingle, James N; Pritchard, Kathleen I et al. (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375:209-19|
|Lichtman, Stuart M; Cirrincione, Constance T; Hurria, Arti et al. (2016) Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. J Clin Oncol 34:699-705|
|Belani, Chandra P; Dahlberg, Suzanne E; Rudin, Charles M et al. (2016) Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer 122:2371-8|
|Luskin, Marlise R; Lee, Ju-Whei; Fernandez, Hugo F et al. (2016) Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood 127:1551-8|
|Kent, Michael S; Mandrekar, Sumithra J; Landreneau, Rodney et al. (2016) Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance). Ann Thorac Surg 102:230-8|
|Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112|
Showing the most recent 10 out of 36 publications